Summary | Specialty drug costs are sky high, and insurers,
doctors and hospitals are pushing back in a phenomenon that
played out during the most recent proxy season. One large
pension plan was keen on finding out whether some
pharmaceutical companies are at risk of pricing themselves out
of the game. ...
blogs.wsj.com | 16 July 2015